CA2262267C - Compositions pharmaceutiques contre la migraine et methode d'utilisation - Google Patents

Compositions pharmaceutiques contre la migraine et methode d'utilisation Download PDF

Info

Publication number: CA2262267C
Authority: CA; Canada
Prior art keywords: tramadol; migraine; antiemetic; group; composition
Prior art date: 1998-02-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 2262267

Other languages

English (en)

Other versions

CA2262267A1 (fr

Inventor

Marc Raber

Helmut Momberger

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Meda Pharma GmbH and Co KG

Original Assignee

Viatris GmbH and Co KG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-20

Filing date

1999-02-19

Publication date

2007-05-08

1999-02-19 Application filed by Viatris GmbH and Co KG filed Critical Viatris GmbH and Co KG

1999-08-20 Publication of CA2262267A1 publication Critical patent/CA2262267A1/fr

2007-05-08 Application granted granted Critical

2007-05-08 Publication of CA2262267C publication Critical patent/CA2262267C/fr

2019-02-19 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

230000002460 anti-migrenic effect Effects 0.000 title abstract description 7
238000000034 method Methods 0.000 title abstract description 6
230000008569 process Effects 0.000 title abstract description 5
239000008194 pharmaceutical composition Substances 0.000 title description 3
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims abstract description 57
229960004380 tramadol Drugs 0.000 claims abstract description 56
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims abstract description 54
239000000203 mixture Substances 0.000 claims abstract description 46
239000002111 antiemetic agent Substances 0.000 claims abstract description 35
230000003474 anti-emetic effect Effects 0.000 claims abstract description 34
150000001875 compounds Chemical class 0.000 claims abstract description 9
208000019695 Migraine disease Diseases 0.000 claims description 51
206010027599 migraine Diseases 0.000 claims description 36
238000011282 treatment Methods 0.000 claims description 27
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 23
229960004503 metoclopramide Drugs 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 12
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 7
239000000739 antihistaminic agent Substances 0.000 claims description 7
239000003210 dopamine receptor blocking agent Substances 0.000 claims description 7
229950000688 phenothiazine Drugs 0.000 claims description 7
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 7
229960001253 domperidone Drugs 0.000 claims description 6
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 4
PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 4
DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 claims description 4
229960000876 cinnarizine Drugs 0.000 claims description 4
229960003564 cyclizine Drugs 0.000 claims description 4
UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 claims description 4
229960004993 dimenhydrinate Drugs 0.000 claims description 4
MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 4
229960003727 granisetron Drugs 0.000 claims description 4
MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 4
229960005343 ondansetron Drugs 0.000 claims description 4
229960003111 prochlorperazine Drugs 0.000 claims description 4
WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims description 4
229960003910 promethazine Drugs 0.000 claims description 4
229960003688 tropisetron Drugs 0.000 claims description 4
UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims description 4
229940125684 antimigraine agent Drugs 0.000 claims description 3
239000002282 antimigraine agent Substances 0.000 claims description 3
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 6
230000001387 anti-histamine Effects 0.000 claims 6
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 9
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
206010019233 Headaches Diseases 0.000 description 22
230000000694 effects Effects 0.000 description 22
231100000869 headache Toxicity 0.000 description 22
208000002193 Pain Diseases 0.000 description 19
230000000202 analgesic effect Effects 0.000 description 18
230000036407 pain Effects 0.000 description 16
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
239000000243 solution Substances 0.000 description 14
239000004480 active ingredient Substances 0.000 description 10
206010047700 Vomiting Diseases 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
239000000730 antalgic agent Substances 0.000 description 8
238000009472 formulation Methods 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 7
229940035676 analgesics Drugs 0.000 description 7
229940125683 antiemetic agent Drugs 0.000 description 7
239000002775 capsule Substances 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
IRQVJPHZDYMXNW-UHFFFAOYSA-N metoclopramide dihydrochloride monohydrate Chemical compound O.[Cl-].[Cl-].CC[NH+](CC)CCNC(=O)C1=CC(Cl)=C([NH3+])C=C1OC IRQVJPHZDYMXNW-UHFFFAOYSA-N 0.000 description 7
229960000923 metoclopramide hydrochloride Drugs 0.000 description 7
229940005483 opioid analgesics Drugs 0.000 description 7
229940076279 serotonin Drugs 0.000 description 7
239000012085 test solution Substances 0.000 description 7
229960003107 tramadol hydrochloride Drugs 0.000 description 7
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
229960003708 sumatriptan Drugs 0.000 description 6
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 6
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 5
239000001856 Ethyl cellulose Substances 0.000 description 5
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
206010028813 Nausea Diseases 0.000 description 5
229960003133 ergot alkaloid Drugs 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
235000019325 ethyl cellulose Nutrition 0.000 description 5
229920001249 ethyl cellulose Polymers 0.000 description 5
230000006872 improvement Effects 0.000 description 5
239000005414 inactive ingredient Substances 0.000 description 5
239000008188 pellet Substances 0.000 description 5
235000010241 potassium sorbate Nutrition 0.000 description 5
239000004302 potassium sorbate Substances 0.000 description 5
229940069338 potassium sorbate Drugs 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
229910002012 Aerosil® Inorganic materials 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
229920001800 Shellac Polymers 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
229960004943 ergotamine Drugs 0.000 description 4
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 4
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
230000008693 nausea Effects 0.000 description 4
239000000014 opioid analgesic Substances 0.000 description 4
229960005489 paracetamol Drugs 0.000 description 4
239000008213 purified water Substances 0.000 description 4
230000035807 sensation Effects 0.000 description 4
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 4
239000004208 shellac Substances 0.000 description 4
229940113147 shellac Drugs 0.000 description 4
235000013874 shellac Nutrition 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000008673 vomiting Effects 0.000 description 4
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 3
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
208000000060 Migraine with aura Diseases 0.000 description 3
208000007920 Neurogenic Inflammation Diseases 0.000 description 3
108090000189 Neuropeptides Proteins 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229960001138 acetylsalicylic acid Drugs 0.000 description 3
239000002579 antinauseant Substances 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
229960005070 ascorbic acid Drugs 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical class [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
239000000969 carrier Substances 0.000 description 3
229920002678 cellulose Chemical class 0.000 description 3
239000001913 cellulose Chemical class 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
235000019700 dicalcium phosphate Nutrition 0.000 description 3
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000001525 mentha piperita l. herb oil Substances 0.000 description 3
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
230000000926 neurological effect Effects 0.000 description 3
235000019477 peppermint oil Nutrition 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
229960003415 propylparaben Drugs 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000000454 talc Substances 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
230000024883 vasodilation Effects 0.000 description 3
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
108010011485 Aspartame Proteins 0.000 description 2
206010010774 Constipation Diseases 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
108700002232 Immediate-Early Genes Proteins 0.000 description 2
206010027603 Migraine headaches Diseases 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
206010038776 Retching Diseases 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000000605 aspartame Substances 0.000 description 2
235000010357 aspartame Nutrition 0.000 description 2
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
229960003438 aspartame Drugs 0.000 description 2
210000000133 brain stem Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960000913 crospovidone Drugs 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
150000002314 glycerols Chemical class 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
229960001021 lactose monohydrate Drugs 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
-1 methyloxypropyl Chemical group 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
210000000929 nociceptor Anatomy 0.000 description 2
108091008700 nociceptors Proteins 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
230000000474 nursing effect Effects 0.000 description 2
230000008533 pain sensitivity Effects 0.000 description 2
230000003950 pathogenic mechanism Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000008313 sensitization Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000032106 Complicated migraine Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 description 1
206010016334 Feeling hot Diseases 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019476 Hemiplegic migraine Diseases 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000195947 Lycopodium Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
102400000097 Neurokinin A Human genes 0.000 description 1
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
101800000399 Neurokinin A Proteins 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
208000000114 Pain Threshold Diseases 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000037048 Prodromal Symptoms Diseases 0.000 description 1
208000035755 Psychosomatic disease Diseases 0.000 description 1
206010039677 Scintillating scotoma Diseases 0.000 description 1
206010039729 Scotoma Diseases 0.000 description 1
208000036366 Sensation of pressure Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
208000013521 Visual disease Diseases 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229960002133 almotriptan Drugs 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
230000001458 anti-acid effect Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
229940005486 antimigraine preparations Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000027455 binding Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000003727 cerebral blood flow Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229960004704 dihydroergotamine Drugs 0.000 description 1
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
229960002472 eletriptan Drugs 0.000 description 1
OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000005176 gastrointestinal motility Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000001288 gastroparesis Diseases 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
208000018548 hypothalamic dysfunction Diseases 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
206010052787 migraine without aura Diseases 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
229960005254 naratriptan Drugs 0.000 description 1
UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
229940121367 non-opioid analgesics Drugs 0.000 description 1
235000014593 oils and fats Nutrition 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940051877 other opioids in atc Drugs 0.000 description 1
230000037040 pain threshold Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229960000292 pectin Drugs 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000003236 psychic effect Effects 0.000 description 1
230000010349 pulsation Effects 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
229960000425 rizatriptan Drugs 0.000 description 1
TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
229940032147 starch Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960002324 trifluoperazine Drugs 0.000 description 1
ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
208000029257 vision disease Diseases 0.000 description 1
230000001755 vocal effect Effects 0.000 description 1
229960001360 zolmitriptan Drugs 0.000 description 1
UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 2262267 1998-02-20 1999-02-19 Compositions pharmaceutiques contre la migraine et methode d'utilisation Expired - Fee Related CA2262267C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7533298P	1998-02-20	1998-02-20
US60/075,332		1998-02-20

Publications (2)

Publication Number	Publication Date
CA2262267A1 CA2262267A1 (fr)	1999-08-20
CA2262267C true CA2262267C (fr)	2007-05-08

Family

ID=29581917

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2262267 Expired - Fee Related CA2262267C (fr)	1998-02-20	1999-02-19	Compositions pharmaceutiques contre la migraine et methode d'utilisation

Country Status (1)

Country	Link
CA (1)	CA2262267C (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0108930D0 (en) *	2001-04-10	2001-05-30	Boots Co Plc	Therapeutic agents
EP2124556B1 (fr)	2006-10-09	2014-09-03	Charleston Laboratories, Inc.	Compositions pharmaceutiques
ES2620672T3 (es)	2008-01-09	2017-06-29	Charleston Laboratories, Inc.	Comprimidos de doble capa que comprenden oxicodona y prometazina
WO2011006012A1 (fr)	2009-07-08	2011-01-13	Charleston Laboratories Inc.	Compositions pharmaceutiques
JP2019507181A (ja)	2016-03-04	2019-03-14	チャールストンラボラトリーズ，インコーポレイテッド	医薬組成物

1999
- 1999-02-19 CA CA 2262267 patent/CA2262267C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2262267A1 (fr)	1999-08-20

Legal Events

Date	Code	Title	Description
2002-05-22	EEER	Examination request
2018-04-02	MKLA	Lapsed	Effective date: 20180219

Publication	Publication Date	Title
US6376550B1 (en)	2002-04-23	Pharmaceutical compositions containing tramadol for migraine
AU748993B2 (en)	2002-06-13	Pharmaceutical combinations containing tramadol
US20110274628A1 (en)	2011-11-10	Nicotine-containing pharmaceutical compositions
JP3194734B2 (ja)	2001-08-06	迅速作用性選択的セロトニン再摂取阻害剤を用いた性的不全の処置方法
CA2336095A1 (fr)	1999-12-29	Formes posologiques contenant de l'apomorphine pour ameliorer un dysfonctionnement de l'erection chez l'homme
TWI331920B (en)	2010-10-21	Unit dosage form for relieving or treating constipation in human patients
CA2464261A1 (fr)	2003-05-01	Forme posologique contenant de l'apomorphine pour l'amelioration de la dyserection male
JP5561885B2 (ja)	2014-07-30	ミルタザピンの新しい配合物
CA2262267C (fr)	2007-05-08	Compositions pharmaceutiques contre la migraine et methode d'utilisation
TW200405818A (en)	2004-04-16	Side effect alleviator of diclofenac
US20060269598A1 (en)	2006-11-30	Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use
HU206830B (en)	1993-01-28	Process for producing pharmaceutical compositions containing pafantagonists for treating heart diseases produced by diminished beta-receptor-stimulant
HUP0201650A2 (hu)	2002-12-28	Amino-tetralin-származékok alkalmazása szív- és érrendszeri betegségek gyógykezelésére használható gyógyszerek előállítására
HK1035143B (en)	2004-08-20	Pharmaceutical combinations containing tramadol for the production of a medicament for the treatment of migraine or migrainoid headaches
MXPA00007922A (en)	2001-07-09	Pharmaceutical combinations containing tramadol
JP2025521597A (ja)	2025-07-10	過活動膀胱症候群を治療または予防する方法
JP2002541100A (ja)	2002-12-03	ヒトの性的応答を調節するための方法
HK1093890A (en)	2007-03-16	Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction